Roche Holding AG
RHHBY
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
103,249
Stocks News & Analysis
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
stocks
The 10 best global companies to invest in now
These undervalued stocks of high-quality companies are attractive investments today.
stocks
5 top US dividend shares from the best managers
These cheap dividend stocks are popular among highly rated concentrated fund managers.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,913.90 | 352.20 | 4.66% |
| CAC 40 | 7,126.02 | 263.00 | 3.83% |
| DAX 40 | 20,562.73 | 891.85 | 4.53% |
| Dow JONES (US) | 38,807.41 | 1,801.04 | -4.44% |
| FTSE 100 | 7,913.25 | 233.77 | 3.04% |
| HKSE | 20,681.78 | 417.29 | 2.06% |
| NASDAQ | 16,084.63 | 1,040.35 | -6.08% |
| Nikkei 225 | 34,609.00 | 2,894.97 | 9.13% |
| NZX 50 Index | 12,201.43 | 394.88 | 3.34% |
| S&P 500 | 5,171.92 | 284.98 | -5.22% |
| S&P/ASX 200 | 7,709.60 | 334.60 | 4.54% |
| SSE Composite Index | 3,223.64 | 36.83 | 1.16% |